Download PDF
CC BY-NC-ND 4.0 · South Asian J Cancer 2015; 04(03): 115-117
DOI: 10.4103/2278-330X.173164
GENITOURINARY : Original Article

Human epidermal growth factor receptor 2/neu overexpression in urothelial carcinoma of the bladder and its prognostic significance: Is it worth hype?

Santosh Kumar
Department of Urology, Postgraduate Institute of Medical Education and Research, Chandigarh
,
Omprakash Prajapati
Department of Surgery, Postgraduate Institute of Medical Education and Research, Chandigarh
,
Kim Vaiphei
Department of Pathology, Postgraduate Institute of Medical Education and Research, Chandigarh
,
Kalpesh Mahesh Parmar
Department of Urology, Postgraduate Institute of Medical Education and Research, Chandigarh
,
A. S. Sriharsha
Department of Urology, Postgraduate Institute of Medical Education and Research, Chandigarh
,
S.K Singh
Department of Pathology, Postgraduate Institute of Medical Education and Research, Chandigarh
› Author Affiliations Source of Support: Nill.
› Further Information
Also available at
  PDF Download Permissions and Reprints

Abstract

Aims: In urothelial tumors of the urinary bladder, human epidermal growth factor receptor 2 (HER-2)/neu expression has been reported over 10 years, but there is no clear correlation between prognosis and recurrence rate. The present study evaluates prognostic implication of HER-2/neu expression. Subjects and Methods: In this study, 100 formalin-fixed paraffin-embedded specimens of primary transitional cell carcinoma of the bladder were processed. HER-2/neu monoclonal antibody immunohistochemistry staining procedure used for the study. Results: A total of 70 (70%) patients were positive for overexpression of HER-2/neu. HER-2/neu was positive in patients with 42 (70%) superficial tumor, 28 (70%) muscle invasive tumor, 41 (75.9%) high-grade tumor, 29 (63%) low grade tumor, 31 (68.9%) recurrent tumor, and 6 (66.6%) had positive lymph nodes. Conclusions: Human epidermal growth factor receptor 2/neu over expression was not correlated with the tumor stage, lymphnode metastasis or recurrence of the disease. HER-2/neu overexpression was statistically insignificantly correlated with the differentiation grade (P < 0.161) as compared to previous studies. Future studies on HER-2 expression with chemo-sensitivity and efficacy of HER-2-targeted therapies in urothelial carcinomas is needed.

Key words

C-erbB2 gene - human epidermal growth factor receptor 2/neu - immunohistochemistry - urothelial cancer


Publication History

Article published online:
31 December 2020

© 2015. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Ploeg M, Aben KK, Kiemeney LA. The present and future burden of urinary bladder cancer in the world. World J Urol 2009;27:289-93.
  • 2 Latif Z, Watters AD, Dunn I, Grigor KM, Underwood MA, Bartlett JM. HER2/neu overexpression in the development of muscle-invasive transitional cell carcinoma of the bladder. Br J Cancer 2003;89:1305-9.
  • 3 Stern DF. Tyrosine kinase signalling in breast cancer: ErbB family receptor tyrosine kinases. Breast Cancer Res 2000;2:176-83.
  • 4 Zhau HE, Zhang X, von Eschenbach AC, Scorsone K, Babaian RJ, Ro JY, et al. Amplification and expression of the c-erb B-2/neu proto-oncogene in human bladder cancer. Mol Carcinog 1990;3:254-7.
  • 5 Krüger S, Weitsch G, Büttner H, Matthiensen A, Böhmer T, Marquardt T, et al. Overexpression of c-erbB-2 oncoprotein in muscle-invasive bladder carcinoma: Relationship with gene amplification, clinicopathological parameters and prognostic outcome. Int J Oncol 2002;21:981-7.
  • 6 Lipponen P, Eskelinen M, Syrjänen S, Tervahauta A, Syrjänen K. Use of immunohistochemically demonstrated c-erb B-2 oncoprotein expression as a prognostic factor in transitional cell carcinoma of the urinary bladder. Eur Urol 1991;20:238-42.
  • 7 Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A 1992;89:4285-9.
  • 8 Berger MS, Greenfield C, Gullick WJ, Haley J, Downward J, Neal DE, et al. Evaluation of epidermal growth factor receptors in bladder tumours. Br J Cancer 1987;56:533-7.
  • 9 Tetu B, Fradet Y, Allard P, Veilleux C, Roberge N, Bernard P. Prevalence and clinical significance of HER/2neu, p53 and Rb expression in primary superficial bladder cancer. J Urol 1996;155:1784-8.
  • 10 Vollmer RT, Humphrey PA, Swanson PE, Wick MR, Hudson ML. Invasion of the bladder by transitional cell carcinoma: Its relation to histologic grade and expression of p53, MIB-1, c-erb B-2, epidermal growth factor receptor, and bcl-2. Cancer 1998;82:715-23.
  • 11 Alexa A, Baderca F, Zahoi DE, Lighezan R, Izvernariu D, Raica M. Clinical significance of HER2/neu overexpression in urothelial carcinomas. Rom J Morphol Embryol 2010;51:277-82.
  • 12 Liedberg F, Anderson H, Chebil G, Gudjonsson S, Höglund M, Lindgren D, et al. Tissue microarray based analysis of prognostic markers in invasive bladder cancer: Much effort to no avail? Urol Oncol 2008;26:17-24.
  • 13 Chakravarti A, Winter K, Wu CL, Expression of the epidermal growth factor receptor and Her-2 are predictors of favourable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and Cisplatin-based chemotherapy: A report from the radiation therapy oncology group. Int J Radiat Oncol Biol Phys 2005;62:309-17.
  • 14 Matsubara H, Yamada Y, Naruse K, Nakamura K, Aoki S, Taki T, et al. Potential for HER-2/neu molecular targeted therapy for invasive bladder carcinoma: Comparative study of immunohistochemistry and fluorescent in situ hybridization. Oncol Rep 2008;19:57-63.